|Dr. Robert James Wills||Exec. Chairman||335.26k||N/A||1954|
|Mr. Marc S. Hanover||Co-Founder, CEO & Director||620.77k||N/A||1963|
|Mr. Henry P. Doggrell||VP, Chief Legal Officer, Gen. Counsel & Sec.||479.32k||N/A||1949|
|Mr. Jason T. Shackelford||VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller||N/A||N/A||1975|
|Dr. Diane C. Young M.D.||Chief Medical Officer and VP||N/A||N/A||1957|
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
GTx, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.